Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $75.4 million.

  • Krystal Biotech's Free Cash Flow rose 4318.36% to $75.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $188.9 million, marking a year-over-year increase of 6438.31%. This contributed to the annual value of $188.9 million for FY2025, which is 6438.31% up from last year.
  • Latest data reveals that Krystal Biotech reported Free Cash Flow of $75.4 million as of Q4 2025, which was up 4318.36% from $38.0 million recorded in Q3 2025.
  • Krystal Biotech's 5-year Free Cash Flow high stood at $75.4 million for Q4 2025, and its period low was -$61.8 million during Q4 2021.
  • In the last 5 years, Krystal Biotech's Free Cash Flow had a median value of -$15.0 million in 2021 and averaged -$3.3 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 23739.59% in 2022, then soared by 128750.0% in 2025.
  • Krystal Biotech's Free Cash Flow (Quarter) stood at -$61.8 million in 2021, then surged by 55.41% to -$27.5 million in 2022, then skyrocketed by 71.22% to -$7.9 million in 2023, then skyrocketed by 763.95% to $52.6 million in 2024, then soared by 43.18% to $75.4 million in 2025.
  • Its Free Cash Flow stands at $75.4 million for Q4 2025, versus $38.0 million for Q3 2025 and $50.8 million for Q2 2025.